Cartesian Therapeutics

What Cartesian Therapeutics does

Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-engineered CAR-T cell therapies for autoimmune diseases. Founded in 2016 and headquartered in Frederick, Maryland, the company became publicly traded on NASDAQ (RNAC) in November 2023 via a reverse merger with Selecta Biosciences. Its lead candidate, Descartes-08, is an autologous mRNA CAR-T therapy targeting B-cell maturation antigen (BCMA), currently in Phase 3 development for generalized myasthenia gravis (AURORA trial, approximately 100 patients) with topline data expected in Q1 2027. The pipeline has expanded into myositis (Phase 2 TRITON), juvenile dermatomyositis (Phase 1/2 HELIOS), and systemic lupus erythematosus (Phase 2), while a next-generation candidate, Descartes-15, is paused to prioritize the Descartes-08 programs.

The company's core technology is a proprietary mRNA cell therapy platform that enables transient CAR expression without genomic integration, eliminating the requirement for lymphodepleting chemotherapy and supporting outpatient administration. Cartesian operates a wholly-owned cGMP manufacturing facility in Frederick, Maryland with both clinical and commercial-scale capacity. The platform has received FDA Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Rare Pediatric Disease designations.

Cartesian is pre-revenue with no commercial products; Q1 2026 revenue of $0.95 million is immaterial and likely collaboration-related. The go-to-market strategy centers on advancing through FDA-agreed clinical protocols, securing regulatory designations, and preparing specialty pharmacy and hospital distribution for potential commercialization of Descartes-08. As of Q1 2026, cash stood at $120.4 million; in May 2026 the company secured up to $150 million in non-dilutive debt financing from K2 HealthVentures ($50 million initial tranche), extending runway into 2028. Full-year 2025 net loss was $130.3 million, reflecting aggressive Phase 3 R&D investment.

Name

Cartesian Therapeutics

Legal name

Cartesian Therapeutics, Inc.

Website

https://cartesiantherapeutics.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-engineered CAR-T cell therapies for autoimmune diseases, with lead candidate Descartes-08 in Phase 3 for generalized myasthenia gravis and additional programs in myositis, JDM, and SLE.

Ownership category

akta.pro rank

Product category

mRNA Cell Therapy / CAR-T Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Developers (Autologous) (HLAAABAA), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• MRNA cell therapy
• CAR-T autoimmune
• BCMA targeted therapy
• Cell therapy manufacturing
• RNA engineered therapeutics

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pre-commercial / Clinical Stage Revenue: Cartesian Therapeutics is a clinical-stage biopharmaceutical company and is pre-revenue. The company is developing mRNA cell therapies for autoimmune diseases with lead candidate Descartes-08 in Phase 3 development for myasthenia gravis. No commercial products are currently being sold.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing autologous mRNA-engineered CAR-T cell therapies that target B-cell maturation antigen (BCMA) to treat autoimmune diseases. Its lead candidate Descartes-08 is in Phase 3 development for generalized myasthenia gravis, with additional programs in myositis, systemic lupus erythematosus, and juvenile dermatomyositis. The platform is designed to allow outpatient dosing without preconditioning chemotherapy and without genomic integration risk.

Product overview

Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases. The company's portfolio centers on two mRNA-engineered CAR-T cell therapy candidates: Descartes-08, the lead product in Phase 3 development for generalized myasthenia gravis and Phase 2 for myositis and systemic lupus erythematosus, and Descartes-15, a next-generation BCMA-directed therapy for multiple myeloma currently on pause. Both products leverage the company's proprietary mRNA cell therapy platform enabling outpatient administration without pretreatment chemotherapy.

Differentiator

Problem solved

Functional benefit

Products and services

• Descartes-08 Autologous mRNA-engineered chimeric antigen receptor T-cell (mRNA CAR-T) therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases including generalized myasthenia gravis, systemic lupus erythematosus, myositis, and juvenile dermatomyositis. Designed for outpatient dosing without preconditioning chemotherapy and without genomic integration.
• Descartes-15 Next-generation autologous BCMA-directed mRNA-engineered CAR-T cell therapy with approximately ten-fold increase in CAR expression compared to Descartes-08 in preclinical studies and predictable, controllable pharmacokinetics. Designed to eliminate the need for preconditioning chemotherapy. Originally developed for multiple myeloma; development paused to prioritize Descartes-08 in autoimmune indications.

Quantifiable outcome

• 57% of MG patients achieved minimal symptom expression by month 6, maintaining remission through month 12 in Phase 2b trial
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• WestGene BiopharmacoreStrategic or Co-development Partner · 1 June 2026Strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases using Cartesian's Descartes-08 mRNA payload delivered via WestGene's targeted lipid nanoparticle platform. Companies plan to initiate a Phase 1 dose-escalation study in patients with generalized myasthenia gravis in H2 2026, with clinical data anticipated in H1 2027. WestGene receives an upfront payment and is eligible for potential development and commercial milestone payments.
• Selecta BiosciencescoreStrategic or Co-development Partner · 1 November 2023Reverse merger between Selecta Biosciences and Cartesian Therapeutics completed November 2023, with Cartesian's company name retained. Combined entity listed as RNAC on NASDAQ with over $110 million in cash to support clinical development. The merger created a publicly traded company focused on RNA cell therapies for autoimmune diseases.
• National Institutes of Health (NIH)coreStrategic or Co-development Partner · 1 May 2021$2 million NIH grant to support clinical development of Descartes-30, an RNA cell therapy targeting respiratory diseases. NIH collaboration for RNA cell therapy applications beyond oncology into respiratory and critical care medicine. Company has also obtained grants for therapies in multiple myeloma and myasthenia gravis.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Novartis: Global pharmaceutical company and pioneer in cell therapy with KYMRIAH, the first FDA-approved CAR-T. Comparable as a broad incumbent in cell therapy with growing interest in autoimmune applications, representing both a potential strategic acquirer and a competitor with deep cell therapy commercialization expertise.
• Johnson & Johnson (Janssen): Major pharmaceutical company with CARVYKTI (BCMA-directed CAR-T co-developed with Legend Biotech) for multiple myeloma and active autoimmune pipeline expansion. Comparable as the BCMA CAR-T incumbent whose technology directly parallels Cartesian's BCMA target selection, representing both competitive threat and partnership potential.
• Bristol Myers Squibb: Major pharmaceutical company with established CAR-T franchises (BREYANZI, ABECMA) and a broad autoimmune and immunology portfolio. Comparable as a large incumbent exploring CAR-T expansion into autoimmune diseases, providing both partnership potential and competitive threat to Cartesian.

Emerging players

• Nkarta: Clinical-stage biotech developing allogeneic and autologous NK cell-based therapies engineered with CAR constructs for oncology and autoimmune diseases. Comparable as an emerging cell therapy peer targeting autoimmune indications with an alternative immune cell platform (NK vs T-cell).
• Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR genome editing, with oncology and autoimmune programs. Comparable as an emerging cell therapy peer exploring both autologous and allogeneic approaches in autoimmune disease.
• CRISPR Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-edited cell therapies (CASGEVY) for hemoglobinopathies and oncology, with growing autoimmune pipeline. Comparable as a peer using gene-editing approaches to engineer cell therapies, with potential overlap in autoimmune indications and cell therapy infrastructure.
• Arcellx: Clinical-stage cell therapy company developing CAR-T therapies using a novel D-Domain binder platform, with programs in multiple myeloma and expanding into autoimmune diseases. Comparable as an emerging cell therapy developer with novel technology approaches similar in stage and ambition to Cartesian.
• Allogene Therapeutics: Clinical-stage biotech developing allogeneic (off-the-shelf) CAR-T cell therapies for oncology and autoimmune diseases. Comparable as an emerging peer developing next-generation cell therapy modalities that could compete with or complement autologous approaches like Cartesian's Descartes-08.

Direct peers

• Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies (CABA-201, a CD19-directed CAR-T) for autoimmune diseases including myasthenia gravis, lupus, and other B-cell-mediated conditions. Direct competitor to Cartesian's Descartes-08 in autoimmune cell therapy with overlapping target indications and clinical-stage development.
• Kyverna Therapeutics: Clinical-stage cell therapy company developing CD19-directed CAR-T therapies (KYV-101) for autoimmune diseases including myasthenia gravis, multiple sclerosis, and lupus. Direct competitor with similar autologous CAR-T approach and overlapping autoimmune indications to Cartesian's Descartes-08.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CartesianTX
• LinkedInlinkedin.com/company/cartesian-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cartesian Therapeutics